Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease
NCT02435914
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
236
Enrollment
INDUSTRY
Sponsor class
Conditions
Dry Eye Syndromes
Interventions
DRUG:
AGN-223575 ophthalmic solution
DRUG:
AGN-223575 vehicle ophthalmic solution
Sponsor
Allergan